Skip to main content

Table 3 Correlations between bone markers, inflammatory variables and IGFSD at different time-points and changes in bone mineral density during 24 months for the two treatment groups

From: Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study

  Prednisolone group No prednisolone group
  Δ BMD L2 toL4, 0 to 24 months Δ BMD neck, 0 to 24 months Δ BMD L2 to L4, 0 to 24 months Δ BMD neck, 0 to 24 months
Age ns Ns ns ns
BMI, baseline ns r = 0.26, p = 0.031 ns r = 0.39, p < 0.001
P1NP, baseline ns Ns r = -0.36, p = 0.002 ns
P1NP, 12 months r = -0.24, p = 0.057 r = -0.30, p = 0.018 r = -0.37, p = 0.002 ns
ΔP1NP, 0 to 12 months ns ns ns ns
CTX-1, baseline ns ns ns ns
CTX-1, 12 months ns ns r = -0.36, p = 0.002 ns
ΔCTX-1, 0 to12 months ns r = -0.26, p = 0.045 ns ns
1CTP, baseline ns ns ns r = -0.27, p = 0.020
1CTP, 12 months ns r = -0.24, p = 0.059 r = -0.28, p = 0.017 r = -0.22, p = 0.072
Δ1CTP, 0 to 12 months r = -0.29, p = 0.026 r = -0.33, p = 0.010 ns Ns
ESR, baseline ns ns ns r = -0.24, p = 0.031
ESR, 12 months ns ns r = -0.33, p = 0.004 r = -0.22, p = 0.053
CRP, baseline ns ns ns r = -0.28, p = 0.012
CRP, 12 months ns ns r = -0.28, p = 0.015 r = -0.30, p = 0.008
IL-6, baseline ns ns ns ns
IL-6, 12 months ns r = -0.25, p = 0.037 ns ns
IGFSD, baseline r = 0.36, p = 0.003 ns ns ns
IGFSD, 12 months ns ns ns ns
ΔIGFSD, 0 to 12 months r = -0.31, p = 0.017 ns ns r = -0.25, p = 0.038
  1. BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; CTX = C-terminal telopeptides crosslaps; ESR = erythrocyte sedimentation rate; IGFSD = insulin-like growth factor-1, standard deviation scores; IL-6 = interleukin-6; ns = not significant; P1NP = Procollagen type I N-terminal propeptide. Bold p values are statistically significant.